This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
TransEnterix Sells Surgery System to Japanese University
by Zacks Equity Research
TransEnterix, Inc. (TRXC), a global medical technology company, recently announced that it has sold a Senhance Robotic Surgery System to a Japanese customer.
Baxter-Dorizoe Ink Deal to Expand Generic Injectables Line
by Zacks Equity Research
Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company, recently signed an agreement with India-based Dorizoe Lifesciences for expansion of its generic injectables pipeline.
CONMED (CNMD) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Shares of Utica, NY-based leading medical technology player, CONMED Corporation (CNMD) rallied to a new 52-week high of $52.79 on Jun 13, closing a little lower at $52.49.
Luminex's (LMNX) VERIGENE Panels Receive Approval in Japan
by Zacks Equity Research
Luminex Corporation (LMNX) recently announced that Japan's Central Social Insurance Medical Council has approved to provide reimbursement for VERIGENE assays.
Cerner (CERN) to Develop Electronic Health Records System
by Zacks Equity Research
Cerner Corp (CERN) recently announced that it has been chosen by the U.S. Department of Veterans Affairs to develop an electronic health record (EHR) system.
Align Sets Up Manufacturing Center in China, Grows in APAC
by Zacks Equity Research
Align Technology (ALGN) has recently inaugurated a new Invisalign treatment planning facility in Chengdu, China.
Inogen Secures New Direct-to-Consumer Business Facility
by Zacks Equity Research
Inogen, Inc. (INGN) announced that it has secured a new business facility in the Cleveland, OH area.
RTI Surgical Now Part of US-Based Manufacturing Initiative
by Zacks Equity Research
RTI Surgical, Inc. (RTIX) recently announced that it is now part of a US public-private Manufacturing initiative, the Advanced Regenerative Manufacturing Institute.
Quintiles IMS Holdings (Q) Holds Secondary Offering (revised)
by Zacks Equity Research
Q held a secondary offering of 10.6m shares, of which they repurchased $300m worth.
Mead Johnson's Shareholders Approve Reckitt Benckiser Deal
by Zacks Equity Research
Mead Johnson's (MJN) stockholders have okayed the impending merger with Reckitt Benckiser Group.